The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 4.73 — safe zoneOK
Where the revenue comes from
Fiscal 2025, as AbCellera Biologics Inc. reports it. History and quarterly detail are in the app.
- Licensing and royalty revenue$46.9M
- Research fees$27.2M
- Milestone payments$1.0M
Leadership changes
From AbCellera Biologics Inc.'s own filings, the day they're filed.
- Lynn Seely · director · departureeff. 2026-06-30
- Victor Sandor · director · departureeff. 2026-06-01
- Stephen Quake · director · departureeff. 2025-11-10
Latest filings
- 8-K · Company announcement2026-07-06
- 8-K · Company announcement2026-06-17
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-06-05
- 8-K · Company announcement2026-05-11
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about AbCellera Biologics Inc., every answer cited🔒
- The Intelligence Brief — added when AbCellera Biologics Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.